NCT03405831 - Effect of Ivabradine on Exercise Capacity After Heart Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Cardiac Allograft VasculopathyTransplanted Heart Complication

Interventions

DRUG

Ivabradine

Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks

DRUG

Placebo

Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks

Trial Locations (1)

RECRUITING

Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen